Brodalumab ( DrugBank: Brodalumab )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
37	膿疱性乾癬（汎発型）	3
51	全身性強皮症	2

37. 膿疱性乾癬（汎発型）

臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04183881 (ClinicalTrials.gov)	July 4, 2016	29/11/2019	A Phase 4 Clinical Study of Brodalumab	An Extension Study of Brodalumabin Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Art ...	Psoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic Erythrod ...	Drug: Brodalumab 210mg SC	Kyowa Kirin Co., Ltd.	NULL	Completed	18 Years	N/A	All	138	Phase 4	Japan
2	JPRN-JapicCTI-142430	01/2/2014		A Phase 3 Clinical Study of KHK4827	An Extension Study of KHK4827 Subjects with Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthriti ...	Psoriasis	Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the inte ...	Kyowa Hakko Kirin Co., Ltd.	NULL		18		BOTH	165	Phase 3	NULL
3	JPRN-JapicCTI-132057	01/2/2013		An open-label, non-controlled study of KHK4827 in subjects with psoriasis	A Long-Term Study of KHK4827 in Subjects with Pustular Psoriasis (Generalized) and Psoriatic Erythro ...	Psoriasis	Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the inte ...	Kyowa Hakko Kirin Co., Ltd.	NULL		18		BOTH		Phase 3	NULL

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-194761	23/5/2019	17/05/2019	A Phase 3 study of KHK4827 in patients with systemic sclerosis	A Phase 3, placebo-controlled, double-blind comparative study of KHK4827 with an open-label extensio ...	Systemic sclerosis	Intervention name : KHK4827 INN of the intervention : Brodalumab Dosage And administration of the inte ...	Kyowa Kirin Co., Ltd.	NULL	complete	18	70	BOTH	100	Phase 3	Japan
2	JPRN-JapicCTI-173686	06/10/2017	29/08/2017	A Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosis	A Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosis	systemic sclerosis	Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the inte ...	Kyowa Kirin Co., Ltd.	NULL	complete	18	70	BOTH	6	Phase 1	Japan